(Q45231263)

11 December 2017

title

Assessing cost-effectiveness of drug interventions for schizophrenia (English)

1 reference

11 December 2017

1 reference

5

Theo Vos

1 reference

11 December 2017

Anne Magnus

1

1 reference

11 December 2017

Vaughan Carr

series ordinal

2

1 reference

11 December 2017

Cathrine Mihalopoulos

series ordinal

3

1 reference

11 December 2017

Rob Carter

series ordinal

4

1 reference

11 December 2017

publication date

1 January 2005

1 reference

Australian and New Zealand Journal of Psychiatry

11 December 2017

published in

1 reference

11 December 2017

volume

39

1 reference

11 December 2017

issue

1-2

1 reference

11 December 2017

page(s)

44-54

1 reference

Quality of life and new antipsychotics in schizophrenia. Are patients better off?

11 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

The Vermont longitudinal study of persons with severe mental illness, I: Methodology, study sample, and overall status 32 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

Twenty years' follow-up of first psychiatric presentation for schizophrenia: what could have been prevented?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

Recovery from psychotic illness: a 15- and 25-year international follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

Longitudinal studies of schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

The Australian National Survey of Psychotic Disorders: profile of psychosocial disability and its risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

Systematic Reviews in Health Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

Quetelet's index and risk of colon cancer in college alumni

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

Weight gain as a risk factor for clinical diabetes mellitus in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

Patients' subjective experiences of antipsychotics: clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

Myocarditis and cardiomyopathy associated with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

Medication noncompliance and substance abuse among patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

Defining disability in psychosis: performance of the diagnostic interview for psychosis-disability module (DIP-DIS) in the Australian National Survey of Psychotic Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

A meta-analysis of the efficacy of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

Risperidone versus haloperidol: I. Meta-analysis of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

Using the effect size to model change in preference values from descriptive health status

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

Risperidone versus haloperidol: II. Cost-effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

Estimating the costs and benefits of new drug therapies: atypical antipsychotic drugs for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

Cost Analysis of the Treatment of Schizophrenia in the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01509.X

10.1111/J.1440-1614.2005.01509.X

21 January 2018

Identifiers

DOI

1 reference

11 December 2017

1 reference